AstraZeneca announced a $2 billion strategic equity investment in Summit Therapeutics on September 28. The agreement includes a clinical collaboration focused on the development of ivonescimab and sonesitatug vedotin. This partnership aims to advance oncology treatments through the combined expertise and resources of both companies.
